CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib‐resistant chronic myeloid leukaemia

A tyrosine kinase network composed of the TAM receptor AXL and the cytoplasmic kinases LYN and SYK is involved in nilotinib‐resistance of chronic myeloid leukaemia (CML) cells. Here, we show that the E3‐ubiquitin ligase CBL down‐regulation occurring during prolonged drug treatment plays a critical role in this process. Depletion of CBL in K562 cells increases AXL and LYN protein levels, promoting cell resistance to nilotinib. Conversely, forced expression of CBL in nilotinib‐resistant K562 cells (K562‐rn) dramatically reduces AXL and LYN expression and resensitizes K562‐rn cells to nilotinib. A similar mechanism was found to operate in primary CML CD34+ cells. Mechanistically, the E3‐ligase CBL counteracts AXL/SYK signalling, promoting LYN transcription by controlling AXL protein stability. Surprisingly, the role of AXL in resistance was independent of its ligand GAS6 binding and its TK activity, in accordance with a scaffold activity for this receptor being involved in this cellular process. Collectively, our results demonstrate a pivotal role for CBL in the control of a tyrosine kinase network mediating resistance to nilotinib treatment in CML cells. Copyright © 2015 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

[1]  K. Davies,et al.  The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer , 2014, Nature Reviews Cancer.

[2]  F. Penault-Llorca,et al.  Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy , 2014, Oncogene.

[3]  J. Aster,et al.  SYK is a critical regulator of FLT3 in acute myeloid leukemia. , 2014, Cancer cell.

[4]  P. Carmeliet,et al.  Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. , 2013, Blood.

[5]  M. Caligiuri,et al.  Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target. , 2013, Blood.

[6]  G. Robert,et al.  Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells , 2011, Oncotarget.

[7]  D. Bearss,et al.  Targeting Axl and Mer Kinases in Cancer , 2011, Molecular Cancer Therapeutics.

[8]  E. Lippert,et al.  Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells. , 2011, Blood.

[9]  Douglas B. Evans,et al.  Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma , 2011, Cancer.

[10]  D. Mukhopadhyay,et al.  The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. , 2011, Blood.

[11]  Y. Hitoshi,et al.  R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. , 2010, Cancer research.

[12]  Bjørn Tore Gjertsen,et al.  Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival , 2009, Proceedings of the National Academy of Sciences.

[13]  G. Feldmann,et al.  The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target , 2009, Cancer biology & therapy.

[14]  B. Turcq,et al.  Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. , 2008, Cancer research.

[15]  Ming-Tseh Lin,et al.  Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. , 2008, Cancer letters.

[16]  A. Boureux,et al.  The Src-like adaptor protein regulates PDGF-induced actin dorsal ruffles in a c-Cbl-dependent manner , 2008, Oncogene.

[17]  N. Donato,et al.  Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. , 2008, Blood.

[18]  C. Récher,et al.  A critical role for Lyn in acute myeloid leukemia. , 2008, Blood.

[19]  Paloma Valverde,et al.  Effects of Gas6 and hydrogen peroxide in Axl ubiquitination and downregulation. , 2005, Biochemical and biophysical research communications.

[20]  I. Dikic,et al.  Src Phosphorylation of Alix/AIP1 Modulates Its Interaction with Binding Partners and Antagonizes Its Activities* , 2005, Journal of Biological Chemistry.

[21]  W. Cavenee,et al.  Alix/AIP1 Antagonizes Epidermal Growth Factor Receptor Downregulation by the Cbl-SETA/CIN85 Complex , 2004, Molecular and Cellular Biology.

[22]  Sujay K. Singh,et al.  Hydrogen Peroxide Activates NF-κB through Tyrosine Phosphorylation of IκBα and Serine Phosphorylation of p65 , 2003, Journal of Biological Chemistry.

[23]  S. Pierce,et al.  Cbl-b Negatively Regulates B Cell Antigen Receptor Signaling in Mature B Cells through Ubiquitination of the Tyrosine Kinase Syk , 2003, The Journal of experimental medicine.

[24]  A. Scharenberg,et al.  Activation of Syk Tyrosine Kinase Is Required for c-Cbl-mediated Ubiquitination of FcεRI and Syk in RBL Cells* , 2002, The Journal of Biological Chemistry.

[25]  R. Herrmann,et al.  Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK) , 1999, Leukemia.

[26]  J. Melo,et al.  The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. , 1996, Blood.

[27]  D. Huhn,et al.  Axl, a novel receptor tyrosine kinase isolated from chronic myelogenous leukemia. , 1993, Seminars in hematology.

[28]  M. Yoshida,et al.  Characterization of the promoter region of the src family gene lyn and its trans activation by human T-cell leukemia virus type I-encoded p40tax , 1992, Molecular and cellular biology.

[29]  R. Espinosa,et al.  axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase , 1991, Molecular and cellular biology.

[30]  O. Witte,et al.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. , 1990, Science.

[31]  G. Daley,et al.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.

[32]  N. Heisterkamp,et al.  Oncogene activation by chromosomal translocation in chronic myelocytic leukemia. , 1986, Cold Spring Harbor symposia on quantitative biology.

[33]  J. Rowley,et al.  Chromosome abnormalities in malignant hematologic diseases. , 1982, Advances in cancer research.

[34]  W. N.,et al.  THE PATHOLOGICAL SOCIETY OF GREAT BRITAIN AND IRELAND , 1906 .